Anti-cytoplasmic tail of CD4 [8A5]

Antibody developed against a region of CD4 that is only produced if the UGA is read through. Used to determine whether or not the first UGA codon in the 3′ region of CD4 is read through in vivo.

Contributors

Inventor Institute
Brady Neal Ware University of Georgia Research Foundation, Inc.
Cat. #: 162347
Tool sub type: Primary antibody
Unit size: 100 ug
Application: ELISA
Target: RFLPADQMNVADPQPLASCS of human CD4
Reactivity: Human
Host: Mouse
Primary citation: Ware, 2003, Doctoral Thesis, University of Georgia. "Gene regulation and overlooked coding regions : the case for translation past the 3'-UGA codon in CD4"
Product description: Antibody developed against a region of CD4 that is only produced if the UGA is read through. Used to determine whether or not the first UGA codon in the 3' region of CD4 is read through in vivo.
Conjugation: Unconjugated
Isotype: IgM
Immunogen: Peptide
Target background: Amino acids 18-38 past the UGA that may end CD4, includes the predicted alpha helix sequence PADQ. Molecular weight of the peptide for the region past the UGA codon is 2160.6 Daltons. Peptide for the region past the UGA has 10 hydrophilic resides
Format: Liquid
Shipping conditions: Dry ice
References:

Ware, 2003, Doctoral Thesis, University of Georgia. "Gene regulation and overlooked coding regions : the case for translation past the 3'-UGA codon in CD4"

Related Tools for Antibodies

Cat. # Tool Name
151030 Anti-Progesterone [11P14] Key Info View Tool
151016 Anti-CyclinA [E72.1] Key Info View Tool
151019 Anti-Mos [S3.1] Key Info View Tool
151026 Anti-FCGR1 [10.1] mAb Key Info View Tool
151034 Anti-HSVUL42 [13D11] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.